Insulin Human [rDNA] + Isophane Insulin Human: Brands, Price & Uses in Bangladesh

Insulin Human [rDNA] + Isophane Insulin Human is a premixed (biphasic) suspension of short-acting soluble (regular) human insulincombined with intermediate-acting isophane (NPH) human insulin, used to lower blood glucose in people with diabetes mellitus.

• Type 1 diabetes mellitus (established/FDA-approved use) — as part of a regimen to achieve glycemic control in patients who require exogenous insulin.
• Type 2 diabetes mellitus (established/guideline-supported use) — in patients whose blood glucose is not adequately controlled by diet, exercise, weight management, and/or oral antidiabetic agents alone.
• Stress-related hyperglycemia (e.g., during acute illness, infection, surgery, or corticosteroid therapy) — adjunct use, typically short-term and physician-directed.

Insulin Human [rDNA] + Isophane Insulin Human is a fixed-ratio premixed insulin and is not intended for intravenous use, for treatment of diabetic ketoacidosis, or for use in insulin infusion pumps; a short-acting insulin alone is used for those situations.

The dose of Insulin Human [rDNA] + Isophane Insulin Human must be individualized by the treating physician based on blood glucosemonitoring, metabolic needs, target HbA1c, meal pattern, and activity level. Patients must not adjust their owndose without medical advice.

Administration technique

• Give by subcutaneous injection only, generally 15–30 minutes before a meal, into the abdomen, thigh, upper arm, or buttock.
• Rotate injection sites within the same body region with each injection to reduce the risk of lipodystrophy (lumps or pitting under the skin) and to keep insulin absorption consistent.
• Gently roll or invert the vial/pen (do not shake vigorously) to re-suspend the insulin evenly before drawing up or dialing a dose; the suspension should look uniformly cloudy/milky.
• Do not use if the suspension remains clear, contains clumps, or has particles/discoloration after mixing.
• Do not administer intravenously or intramuscularly, and do not use in an insulin infusion pump.
• Do not mix Insulin Human [rDNA] + Isophane Insulin Human with other insulin products in the same syringe unless specifically directed by a physician.

See also Dosage, Administration, Use in Special Populations, and Precautions and Warnings for further detail.

The most common and important adverse effect of Insulin Human [rDNA] + Isophane Insulin Human is hypoglycemia (see Overdose Effects andPrecautions and Warnings). Other reported side effects include:

• Injection-site reactions (redness, swelling, itching, or pain).
• Lipodystrophy (thickening, lumps, or pitting of fat tissue) at sites of repeated injection without rotation.
• Weight gain and, occasionally, peripheral edema (fluid retention), especially when starting insulin or intensifying therapy.
• Hypokalemia (low blood potassium), which can be serious, particularly in patients with cardiac disease or those on potassium-lowering medicines.
• Generalized hypersensitivity reactions — rash, itching, sweating, gastrointestinal upset, and rarely, life-threatening anaphylaxis or angioedema.
• Transient visual disturbance (blurred vision) with initiation of therapy or rapid changes in glucose control, usually resolving with continued treatment.